Cipher Capital’s Corcept Therapeutics CORT Stock Holding History

Cipher Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,719	Closed	-$381K	–	459
2023 Q4	$381K	Buy	+11,719	New	+$322K	0.12%	271

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cipher Capital's CORT Position: Q1 2024 in Review

Cipher Capital sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 11,719 shares — an estimated $381K sold.

Cipher Capital first reported a position in CORT in Q4 2023 and held it in 1 quarter. The position peaked at $381K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

Cipher Capital reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
Cipher Capital sold 11,719 Corcept Therapeutics shares in Q1 2024, an estimated $381K.
Cipher Capital first reported a position in Corcept Therapeutics in Q4 2023 and held it in 1 quarter.
Cipher Capital's Corcept Therapeutics position peaked at $381K in Q4 2023.
287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.